[14C]JMKX003142
DrugParticipants will receive oral [14C]JMKX003142
NCT Number: NCT07463053
A phase 1 healthy volunteer study to assess the excretion and metabolism as well as the absolute bioavailability of oral JMKX003142. The study will be conducted in two parts: Part 1 to assess the mass balance of JMKX003142 using orally administered radiolabelled JMKX003142; part 2 will assess the absolute bioavailability using JMKX003142 and radiolabelled JMKX003142 as intravenous and oral forms
Trial opening soon.
Get Notified18 year–45 year
Male
Interventional
Phase 1
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will receive oral [14C]JMKX003142
Participants will receive oral JMKX003142
Participants will receive IV [14C] JMKX003142
Time frame: up to 15 days (until >90% of dose is recovered)
Total recovery of radioactivity in urine and faeces following a single oral dose of [14C]-JMKX003142 (expressed as a percentage of the total radioactive dose administered)
Time frame: 96 hours
Absolute bioavailability is calculated from the AUCs of iv and oral administration
Time frame: Day 1 to day 15 (depending on recovery of dose)
Time frame: Day 1 to day 15 (depending on recovery of dose)
Time frame: Day 1 to day 15 (depending on recovery of dose)
Time frame: Day 1 to day 15 (depending on recovery of dose)
Time frame: Up to Day 30
Jemincare
Industry
A Study to Evaluate the Mass Balance and Absolute Bioavailability of [14C]JMKX003142 in Healthy Male Participants
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07282821
ADPKD (Autosomal Dominant Polycystic Kidney Disease), Abnormalities, Multiple
Baltimore, Maryland, United States
View Trial DetailsNCT07565441
ADPKD (Autosomal Dominant Polycystic Kidney Disease), Abnormalities, Multiple
View Trial DetailsNCT07470177
ADPKD (Autosomal Dominant Polycystic Kidney Disease), Abnormalities, Multiple
View Trial DetailsNCT06658964
ADPKD (Autosomal Dominant Polycystic Kidney Disease), Abnormalities, Multiple
View Trial Details